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Background and purpose: In patientswith acute decompensated heart failure (ADHF), the prognostic value
of new-onset anemia with regard to renal function has not been investigated.
Methods and subjects: Consecutive 299 ADHF patients (162 men, 62±14 years) were enrolled. Cardio-
vascular (CV) events composite of CV mortality and rehospitalization occurred in 113 patients (37.8%)
during 2 years of follow-up.
Results: Baseline anemia was prevalent (n=124, 41.5%) and 43 patients (14.4%) had new-onset anemia
at 1 month after discharge. Baseline anemia was strongly associated with CV events risk in overall
[hazard ratio (HR): 1.79, 95% CI: 1.17–2.74, p=0.006] and those with preserved renal function [esti-
mated glomerular ﬁltration rate (eGFR)≥45mL/min/1.73m2] (HR: 1.81, 95% CI: 1.05–3.12, p=0.031). In
patients with severe renal dysfunction (eGFR<45mL/min/1.73m2), new-onset anemia independently
predicted CV events (HR: 2.72, 95% CI: 1.09–6.76, p=0.031) whereas baseline anemia did not (HR: 1.28,
95% CI: 0.61–2.65, p=0.505). New-onset anemia was signiﬁcantly associated with hemodilution, which
may reﬂect inadequate decongestion in ADHF patients.
Conclusions: Baseline anemia was an independent prognostic factor in overall ADHF patients and those
with preserved renal function. New-onset anemia as a surrogate for hemodilution better predicted CV
events than baseline anemia in ADHF patients with severe renal dysfunction.
© 2ntroduction
Anemia is a common and well-known predictor of poor prog-
osis in patients with chronic heart failure (HF) [1]. The strong
ssociation between the presence of anemia and mortality in
hronic HF has been demonstrated in numerous studies [2–5].
ew-onset anemia or decrease of hemoglobin level over time was
lso related to increased long-termmortality andmorbidity in sta-
le chronic HF patients [6,7]. In acute decompensated HF (ADHF)
atients, however, a few studies have demonstrated that anemia
t initial presentation was associated with poor prognosis and the
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prognostic value of serial assessment of anemia in ADHF has not
been intensively investigated [8–10].
Renal dysfunction and hemodilution has been known to be
closely interrelated between anemia and adverse outcomes in HF
[11–13]. Ameta-analysis showed that the effect of anemia onmor-
tality attenuated with increasing serum creatinine level [14]. A
recent large HF registry data also showed that baseline anemia
was not an independent predictor of all-cause mortality in outpa-
tients with heart failure with severe renal dysfunction [15]. These
ﬁndings implicate that the prognostic value of baseline anemia
might be attenuated when combined with renal dysfunction not
only in chronic HF, but also in hospitalized ADHF patients. Instead,
serial assessment of anemia reﬂecting hemodilution due to volume
expansion might provide better information on prognosis in ADHF
patients with or without severe renal dysfunction [12]. Thus, we
aimed to study the prognostic value of baseline anemia and new-
onset anemia in ADHF patients according to the presence of severe
renal dysfunction.
llege of Cardiology.
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aterials and methods
tudy population
Three-hundred twenty consecutive patients who visited the
mergency department (ED) of Severance Cardiovascular Hospital,
eoul, Korea between January 2005 and March 2010 with clinical
iagnosis of ADHF were retrospectively investigated in this study,
ollowed up until June 2012. Patients were eligible to be enrolled
n this analysis if they were alive at 1month after hospital dis-
harge. Diagnosis of ADHF was made based on presence of clinical
ymptoms (dyspnea on exertion, orthopnea, or generalized or pul-
onary edema) and left ventricular ejection fraction (LVEF) <50%
easured by two-dimensional trans-thoracic echocardiography.
atients with known hematologic diseases including hemolytic
nemia, presence of cancer, pregnancy, acute bleeding events or
lood transfusion or iron replacement therapy within 3 months or
uring hospitalization, and other extracellular ﬂuid-increasing dis-
ases such as liver cirrhosis were excluded from analysis and 299
atients remained in the analysis. This study was approved by the
nstitutional review board of Severance Hospital.
aboratory measurements
Blood samples were obtained by antecubital venipuncture into
thylenediaminetetraacetic acid-treated or plain tubes at the time
f admission to the ED and at 1 month after discharge. Hemato-
ogic variables such as hemoglobin and hematocrit were measured
sing the Advia 2120i automated analyzer (Siemens Healthcare
iagnostics, Deerﬁeld, IL, USA). Anemia was deﬁned in accor-
ance with the World Health Organization (WHO) as hemoglobin
evels <13.0 g/dL in men and 12.0 g/dL in women. Baseline ane-
ia was deﬁned as anemia at initial presentation and new-onset
nemia was deﬁned as presence of anemia at 1 month after
ischarge without the evidence of baseline anemia. Serum creat-
nine level was calibrated to isotope dilution mass spectrometer
IDMS) method according to international standards. Renal func-
ionwas determined by estimated glomerular ﬁltration rate (eGFR,
L/min/1.73m2) using Chronic Kidney Disease Epidemiology Col-
aboration (CKD-EPI) equation [16]. Severe renal dysfunction was
eﬁned as eGFR<45mL/min/1.73m2. In a prior study about the
ffect of aggressive decongestion on renal function and prognosis,
estani and his colleagues used pairs of surrogate markers includ-
ngdeltaofhematocrit, albumin, and totalproteinas theevidenceof
econgestion [17].We applied this concept to deﬁne hemodilution
ssociated with new-onset anemia in heart failure. Hemodilution
as deﬁned as 2≥3 of delta hematocrit, delta total protein, or
elta albumin in the lowest tertile. Data on loop diuretics dose
eforeadmission, duringhospitalization, andatdischargewere col-
ected and torasemide doseswere converted to dose equivalents to
urosemide using conversion value of 4 [18].
linical outcomes
Detailed follow-up data of all patients including mortality and
ospitalization were retrieved from the electronic medical record
ystem of the hospital. Median follow-up duration after initial
dmissionwas 710 days [interquartile range (IQR) 288–1256 days].
he primary endpoint was cardiovascular (CV) events deﬁned as
omposite of 2-year CVmortality or rehospitalization due to wors-
ning of congestive symptoms by heart failure aggravation, acute
oronary syndrome, arrhythmia, or cardiac arrest.iology 64 (2014) 43–48
Statistical analysis
Continuous variableswere expressed asmean± standarddevia-
tion (SD), median (IQR) and categorical variables as numbers (%).To
compare the baseline and follow-up data, we used one-way anal-
yses of variance (ANOVA) with Bonferroni method, Kruskal–Wallis
test, t-test, and Wilcoxon rank-sum test for continuous vari-
ables and chi-square test for categorical variables as appropriate.
Spearman correlation analysis was used to assess the correlation
between delta of hemoglobin, hematocrit, total protein, albumin,
and eGFR. Comparisons of 2-year CV events among baseline, new-
onset, andnon-anemiagroupsweredonebyKaplan–Meier survival
analyses with log-rank test. Logistic regression analyses were done
to determine the independent association of hemodilution with
new-onset anemia. The independent prognostic value of baseline
anemiaandnew-onset anemiawasassessedusingmultivariateCox
proportional hazard model incorporating covariates with p<0.10
on univariate analysis. No covariates violated proportional haz-
ard assumption. All given p-values are two sided and the level
of statistical signiﬁcance was set to 0.05. All statistical analyses
were performed using STATA 12.0 (Stata Corp, College Station,
TX, USA).
Results
Baseline characteristics of study population
Among a total of 299 patients analyzed in this study, 162
(54%) were men and the mean age was 62.8±14.1 years. Baseline
anemia was found in 132 patients (44.1%) and new-onset ane-
mia at 1 month after discharge occurred in 43 patients (14.4%).
The majority (83.3%) was normocytic [mean corpuscular volume
(MCV) 82–98 fL] and macrocytic anemia and microcytic ane-
mia were observed in 4.4% and 4.4% of patients, respectively.
Baseline characteristics by anemia are presented in Table 1.
Compared with patients with new-onset anemia and with no
anemia, those who had baseline anemia were more likely to
have older age, previous use of higher dose of loop diuretics,
lower renal function, and lower serum albumin level. Patients
with new-onset anemia were associated with lower renal func-
tion, lower baseline hemoglobin level, and lower total doses of
discharge diuretics compared to those without anemia. Among
anemia groups, MCV did not differ and mean corpuscular
hemoglobin (MCH) and mean corpuscular hemoglobin concen-
tration (MCHC) had statistically signiﬁcant but clinically trivial
difference.
During median follow-up of 710 days (IQR 288–1256 days),
2-year CV events as a composite of CV mortality and rehospital-
ization occurred in 113 patients (37.8%) and 30.9% among them
(35/113) had CV mortality. Non-CV mortality occurred only in 1
patient (0.66%).When compared with patients without CV events,
those who had CV events were more likely to be older and to
have lower hemoglobin, hematocrit, eGFR, systolic blood pres-
sure, and sodium level (p<0.05 in all). Prevalence of baseline
anemiawas signiﬁcantlyhigher inCVevents group (56.6%vs. 36.6%,
p<0.001).
Discharge hemoglobin data were available in a subset of 277
patients. Anemia at discharge was present in 166 patients (59.9%)
and 115 patients among them (69.3%) had anemia at admission.
Among patients without anemia at baseline, development of ane-
miaatdischargeoccurred in51patients (33.3%)and theyhadhigher
2-year CV events rate compared to those without development of
anemia (39.2% vs. 24.5%, Log-rank p=0.025). Among patients with
new-onset anemia, 37 (88.1%) had anemia at discharge (p<0.001).
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Table 1
Baseline demographics and clinical characteristics of patients with acute decompensated heart failure.
Variables Baseline anemia
(n=124, 41.5%)
New-onset anemia
(n=43, 14.4%)
No anemia
(n=132, 44.1%)
p-Value
Age (years) 66.2±12.9* 62.6±13.4 59.4±14.9 <0.001
Male sex, n (%) 66 (50.0)* 25 (58.1) 71 (57.3) 0.433
Body mass index (kg/m2) 22.3±3.9 22.5±3.9 23.8±3.8 0.005
Ischemic etiology 46 (34.8) 22 (51.2) 24 (19.4) <0.001
Diabetes 43 (32.6) 14 (32.6) 33 (26.6) 0.542
NYHA III, IV 124 (100.0) 43 (100.0) 132 (100.0) 1.000
Systolic BP (mmHg) 120.9±22.9 117.4±22.6 120.9±23.2 0.659
Ejection fraction (%) 33.7±15.1 36.2±14.9 32.6±15.7 0.437
ACE inhibitors at discharge 97 (79.0) 32 (73.6) 100 (76.2) 0.102
Beta-blocker at discharge 56 (45.3) 23 (53.1) 67 (50.6) 0.224
Aspirin use at discharge 81 (65.4) 29 (67.2) 84 (63.4) 0.695
Loop diuretics at admission (mg/day) 24.8±34.8* 17.8±30.5 14.5±21.1 0.019
Loop diuretics during hospitalization (mg/day) 41.9±37.1 59.6±92.3 40.9±27.1 0.059
Discharge loop diuretics (mg/day) 35.7±36.5 26.9±21.2 35.2±22.7 0.067
Hemoglobin (g/dL) 10.7±1.5* 13.8±1.2† 14.3±1.5 <0.001
Hematocrit (%) 32.4±4.4* 39.3±4.6* † 42.0±5.8 <0.001
MCV (fL) 90.7±7.1 90.7±5.3 90.5±6.6 0.969
MCH (pg) 30.2±2.7 31.2±1.9† 30.6±1.8 0.045
MCHC (g/dL) 33.3±1.3* 34.3±1.2* † 33.7±1.1 <0.001
WBC counts (cells/L) 8113±6509 10,409±4493 8410±3413 0.037
BUN (mg/dL) 29.6±18.1* 23.6±12.8* † 20.1±8.3 <0.001
Creatinine (mg/dL) 2.3±2.8* 1.4±1.2† 1.2±1.7 <0.001
eGFR (mL/min/1.73m2) 52.1±32.3 65.6±26.9 73.8±23.8 <0.001
NT-proBNP (pg/mL) 6102 [3245–13,965]* 6052 [2299–13,629]* 2426 [1146–5267] <0.001
Total cholesterol (mg/dL) 143.9±40.5* 162.3±40.4* † 158.8±39.1 0.005
Sodium (mmol/L) 137.8±4.7 138.1±3.8 139.1±3.6 0.083
Protein (g/dL) 6.7±0.8 6.8±0.8 6.9±0.6 0.109
Albumin (g/dL) 3.9±0.5* 4.1±0.6* † 4.2±0.4 <0.001
Data are presented as mean± standard deviation, median [interquartile range], or number of patients (column %). NYHA, New York Heart Association; ACE, angiotensin-
converting enzyme; BP, blood pressure; SD, standard deviation;MCV,mean corpuscular volume;MCH,mean corpuscular hemoglobin;MCHC,mean corpuscular hemoglobin
concentration; WBC, white blood cell count; BUN, blood urea nitrogen; eGFR, estimated glomerular ﬁltration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide.
P
2
d
w
2
f
m
a
(
w
e
c
3
v
r
p
a
a
p
1
w
h
C
w
a
C
p
t
n
s* Signiﬁcant compared with no anemia group (p<0.05).
† Signiﬁcant compared with baseline anemia group (p<0.05).
rognostic value of baseline anemia and new-onset anemia for
-year CV events in ADHF according to presence of renal
ysfunction
In overall ADHF patients, patients with baseline anemia had
orse 2-year prognosis than those without anemia (48.4% vs.
6.6%, Log-rank p<0.001, Fig. 1). In patients with preserved renal
unction (eGFR≥45mL/min/1.73m2), those with baseline ane-
ia were associated with poor prognosis, whereas new-onset
nemia group and non-anemia group showed similar outcomes
42.2% vs. 24.2% vs. 26.1%, Log-rank p=0.009). In ADHF patients
ith severe renal dysfunction (eGFR<45mL/min/1.73m2), how-
ver, those with new-onset anemia had highest CV events rate
ompared to baseline anemia and non-anemia (80.0% vs. 55.7% vs.
0.7%, Log-rank p=0.046). To assess the independent prognostic
alue, baseline anemia and new-onset anemia were entered sepa-
ately into multivariate Cox-proportional hazardmodel with other
otential predictors and only baseline anemia was independently
ssociated with CV events at 2 years in overall ADHF patients [haz-
rd ratio (HR) 1.79 with 95% conﬁdence interval (CI) 1.18–2.74,
= 0.006, Fig. 2) and in those with preserved renal function (HR
.81, 95% CI 1.05–3.12, p=0.031). Similarly, when hemoglobin
as entered as a continuous variable, 1 g/dL increase of baseline
emoglobin level was associated with 10% reduction of 2-year
V events risk (HR 0.90, 95% CI 0.82–0.99, p=0.032) in patients
ith ADHF. However, the prognostic value of baseline anemia was
ttenuated in those with severe renal dysfunction (HR 1.28, 95%
I 0.61–2.65, p=0.505) whereas new-onset anemia independently
redicted 2-year CV events in those with severe renal dysfunc-
ion (HR 2.72, 95% CI 1.09–6.76, p=0.031). Interaction between
ew-onset anemia and severe renal dysfunction was statistically
igniﬁcant (p for interaction=0.012).Association of hemodilution surrogates with renal function and
anemia in ADHF
To investigate the role of hemodilution on varying prognostic
value of anemia by severe renal dysfunction in ADHF patients, the
complete pairs of follow-up hematocrit, albumin, and total protein
data as a surrogate for hemodilution were analyzed in the sub-
set of 251 patients with available data. Hemodilution was deﬁned
as 2≥3 of lowest tertile in delta hematocrit [<−1.0; median 1.1
(IQR −2.1 to 3.5)], delta total protein [<0.1; 0.3 (IQR −0.1 to 0.8)],
or delta albumin [<0.0; 0.2 (IQR −0.1 to 0.5)]. In overall ADHF
patients, hemodilutionwas observed in 61 patients (24.3%) and the
prevalence was signiﬁcantly higher in those with new-onset ane-
mia compared to those with baseline anemia or without anemia
(41.6% vs. 24.7% vs. 17.7%, p=0.016). Compared to those without
hemodilution, incidence of 2-year CV events was higher in those
with hemodilution with marginal statistical signiﬁcance (45.9% vs.
33.1%, p=0.072) while prevalence of severe renal dysfunction was
similar between two groups (29.5% vs. 25.8%, p=0.568).
Predictors of anemia in ADHF patients by severe renal dysfunction
Compared to patients with preserved renal function (N=215,
eGFR≥45mL/min/1.73m2), patientswith severe renal dysfunction
(N=84, eGFR<45mL/min/1.73m2) had lower baseline hemoglobin
level (11.4 vs. 13.1 g/dL, p<0.001) and higher prevalence of base-
line anemia (72.6% vs. 33.0%, p<0.001). Among 167 patients
without baseline anemia, patients with severe renal dysfunction
(N=23) had higher prevalence of new-onset anemia (43.5% vs.
22.9%, p=0.036) and had a tendency to show larger decrease
in hemoglobin level (−0.8 vs. −0.3, p=0.099) compared to the
preserved renal function group (N=144). In multivariate logistic
46 N. Hong et al. / Journal of Cardiology 64 (2014) 43–48
Fig. 1. Kaplan–Meier survival curve for 2-year cardiovascular events according to
baseline anemia, new-onset anemia, and no anemia in acute decompensated heart
failure (ADHF). (A) Overall, (B) with preserved renal function, and (C) with severe
renal dysfunction. CV, cardiovascular; eGFR, estimated glomerular ﬁltration rate.
Fig. 2. Multivariate-adjusted hazard ratio for 2-year cardiovascular events in
Table 2
Independent predictors for baseline anemia and new-onset anemia in multivariate logist
Variables Univariate
Odds ratio (95% CI)
Predictors for baseline anemia
Age (+1 year) 1.03 (1.01–1.05)
BMI (+1kg/m2) 0.92 (0.87–0.97)
Low eGFR (<45mL/min/1.73m2) 5.37 (3.08–9.39)
Loop diuretics at admission (+20mg/day) 1.25 (1.06–1.47)
Predictors for new-onset anemia
Hemodilution 3.27 (1.42–7.48)
Baseline hemoglobin (+1g/dL) 0.75 (0.57–0.98)
Ischemic etiology 4.36 (2.07–9.20)
Loop diuretics at discharge (+20mg/day) 0.69 (0.49–0.97)
CI, conﬁdence interval; BMI, body mass index, eGFR, estimated glomerular ﬁltration rate.patients with acute decompensated heart failure grouped by presence of severe
renal dysfunction and by anemia status at 1month after discharge. HR, hazard ratio;
CI, conﬁdence inteval; eGFR, estimated glomerular ﬁltration rate.
analyses, old age, impaired renal function, and lowbodymass index
(BMI), and higher doses of previous loop diuretics were signiﬁ-
cantly associated with presence of baseline anemia. Hemodilution,
low baseline hemoglobin, ischemic etiology, and lower doses of
loop diuretics at discharge were the independent predictors of
new-onset anemia (Table 2). When hemodilution was entered
into multivariate logistic model for new-onset anemia, presence of
hemodilutionwas signiﬁcantly associatedwith about 3-fold higher
risk of new-onset anemia [odds ratio (OR) 3.53, 95% CI 1.32–9.43,
p=0.012]. Delta of each surrogate in lowest tertile was also signiﬁ-
cantly associatedwith new-onset anemia except total proteinwith
marginal signiﬁcance (hematocrit, OR 10.95, 95% CI 4.20–28.52,
p<0.001; albumin, OR 2.90, 95% CI 1.12–7.47, p=0.027; total pro-
tein, OR 2.09, 95% CI 0.96–4.58, p=0.063).
Discussion
The principal ﬁndings of this study are as follows: (1) base-
line anemia was prevalent andwas associated with poor prognosis
in overall ADHF patients and in a subgroup with preserved renal
function; (2) in patients with severe renal dysfunction, however,
baseline anemia was not an independent predictor of CV events
whereas presence of new-onset anemia was signiﬁcantly associ-
ated with 2.7-fold increased CV events risk after adjustment for
other potential confounders; and (3) hemodilution was an inde-
pendent predictor of new-onset anemia in ADHF patients.
ic analysis.
Multivariate
p-Value Odds ratio (95% CI) p-Value
<0.001 1.02 (1.00–1.04) 0.046
0.009 0.93 (0.87–0.99) 0.036
<0.001 4.19 (2.34–7.52) <0.001
0.008 1.19 (1.00–1.43) 0.047
0.005 3.53 (1.32–9.43) 0.012
0.039 0.58 (0.41–0.84) 0.004
<0.001 4.23 (1.74–10.29) 0.001
0.035 0.75 (0.50–1.12) 0.169
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Previous studies showed that the prevalence of anemia was rel-
tively high in patients with ADHF (30–68%) and the prevalence of
nemia in our data (44%) was within the range of previous reports
1,8,12]. The strong association between baseline anemia and poor
rognosis in HF patients has been demonstrated in numerous
tudies [2–4,19,20]. In our study, we found independent associa-
ion between baseline anemia and CV events at 2 years in overall
atients and those with preserved renal function, which was con-
istent with previous studies. Linear decrease of CV events risk per
aseline hemoglobin increase as a continuous variable was also
imilar to previous reports [21]. The predictive value of baseline
nemia, however, was attenuated in ADHF patients with severe
enal dysfunction. A large out-patient clinic based registry study
howed that baseline anemia was not an independent predic-
or of all-cause mortality in patients with advanced HF or severe
enal dysfunction, supporting our ﬁndings [15]. In a meta-analysis,
roenveld et al. suggested that the effect of anemia on mortality
eclined with higher serum creatinine levels, which may imply
hat impaired renal function plays a greater role than anemia itself
n association with poor prognosis in ADHF with impaired renal
unction [14].
In our study, new-onset anemia was a strong and independent
redictor of 2-year CV events risk in ADHF patients with severe
enal dysfunction. In large observational and clinical trial studies,
ew-onset anemia was associated with long-term mortality and
orbidity in stable ambulatory HF patients in out-patients settings
6,7]. Maintaining high hemoglobin level, however, was associ-
ted with greater reduction in left ventricular mass index and wall
hickness in HF patients with CKD not on dialysis [22]. Hemod-
lution has been suggested as a potential underlying mechanism
or onset of anemia in HF and poor prognosis [12,23,24]. Androne
t al. reported that the prevalence of hemodilution measured by
131-tagged albumin was high as 46% among advanced HF patients
ith anemia and those with hemodilution had worse prognosis
han those with true anemia [12]. Among HF patients, hemod-
lution was more common in those with lower than preserved
jection fraction [25]. Hemodilution was signiﬁcantly associated
ith development of low hemoglobin level when hemodilution
eﬁned as percentage of plasma volume was entered into mul-
ivariate regression model with other potential confounders for
nemia inHFpatients [24].Weobservedhighprevalenceofhemod-
lution in ADHF patients with new-onset anemia and hemodilution
as a potent independent predictor of new-onset anemia in our
tudy, which supports previous ﬁndings. Previous studies demon-
trated that hemoconcentration was signiﬁcantly associated with
ggressive ﬂuid removal, transient renal function deterioration,
nd substantial improvement in survival, implicating the impor-
anceof aggressivedecongestionduringhospital admission [17,23].
n line with previous ﬁndings, development of anemia at discharge
as signiﬁcantly associated with poor prognosis and new-onset
nemia at 1 month after discharge in this study. Considering the
ifﬁculties in achievingoptimaldecongestion suchasdiuretic resis-
ance in patients with ADHF, it is reasonable to hypothesize that
emodilution signiﬁcantly accounts for onset of anemia and for
ssociation with adverse outcomes in ADHF patients with severe
enal dysfunction [26]. Taken together, our ﬁndings suggest that
ew-onset anemia, a potential indicator of hemodilution leading to
oor prognosis, might provide better prognostic performance than
aseline anemia in ADHF patients with severe renal dysfunction,
lthough further studies are needed to understand the mechanism
learly.
Our study is limited by its retrospective observational design
onducted in a single center. We cannot rule out the possibili-
ies of residual confounding factors and biases, although extensive
tatistical adjustments were done. Patients with in-hospital mor-
ality during ﬁrst admission or CV events within 1 month afteriology 64 (2014) 43–48 47
discharge were not eligible to be enrolled in our study, suggesting
that our studymight not be free from selection bias, although itwas
inevitable due to study design and similar methods were used in
previous studies [7,10]. Arbitrary follow-up duration of 1 month
after discharge was used to deﬁne new-onset anemia based on
short-term follow-up period within 1 month according to similar
previous studies [10,17,27]. Iron proﬁle such as total iron binding
capacity, serum ferritin level, and serumvitaminB12 levelwere not
available in our data, even though we excluded the patients with
acute bleeding events, on transfusion, or on iron replacement ther-
apy and the majority of our patients had MCV and MCHC within
normal range. Hemodilution was deﬁned using surrogate mark-
ers such as the pair of hematocrit, albumin, and total protein in a
subset of our patients. Given the signiﬁcant association between
new-onset anemia and the presence of 2≥3 of delta hematocrit,
delta total protein, or delta albumin in the highest tertile, these
surrogates were considered to provide good evidence of hemod-
ilution, although no direct measurement for plasma volume was
available in our study [17,23,28]. Further studies using direct mea-
surement of volume status are needed to validate this concept. In
our study, we observed that stratiﬁcation by severe renal dysfunc-
tion had signiﬁcant interaction on the association among baseline
anemia, new-onset anemia, and CV events, leading to ambiguous
effect of new-onset anemiaonprognosticationofCVevents in those
withpreserved renal function, although therewasno statistical sig-
niﬁcance. Previous studies with long-term follow-up on anemia in
HF suggested that anemia in HF could be resolved with better con-
trol of ﬂuid status and reversible concomitant conditions and this
transient anemia was associated with similar outcomes compared
with no anemia [6,7]. Considering the short length of follow-up
time and deﬁnition of new-onset anemia in our study setting, it is
conceivable that thosewith new-onset anemia and preserved renal
function might have a higher chance of recovery from transient
anemic status due to remaining kidney function compared to those
with severe renaldysfunction, although it ishypothesis-generating.
Long-term follow-up studies on anemia status, co-morbidities,
ﬂuid status, and responses to standard therapies are needed.
In conclusion, our study suggests that baseline anemia inde-
pendently predicts 2-year CV events risk in overall ADHF patients
and in a subgroup with preserved renal function but not in
those with severe renal dysfunction. New-onset anemia reﬂecting
hemodilution at 1 month after discharge may provide better pro-
gnostic information for CV events than baseline anemia in ADHF
patients with severe renal dysfunction. Repeated measurement of
hemoglobin, a simple low-cost strategy already available in most
clinics, might have important implications on risk stratiﬁcation of
ADHFpatientswith respect to presence of severe renal dysfunction.
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